Equity Ways

20/09/2021

We just touched 10000 subscribers on YouTube.
I never thought of reaching this far. Thank you so much everyone for putting trust in me.
💗

https://www.youtube.com/channel/UCmlRTZWMzu8gt1czH6D3yWg

04/09/2021

How pump & dump works

29/08/2021

Top 10 FMCG Companies in India | भारत की टॉप 10 एफएमसीजी कंपनियां

15/08/2021

The tribute will always be less for our freedom fighters but the salute to all will never be less.
Saluting the entire nation, Happy Independence day! 🇮🇳

15/08/2021

The tribute will always be less for our freedom fighters but the salute to all will never be less.
Saluting the entire nation, Happy Independence day!

27/07/2021

About Rolex Rings Limited –

Incorporated in 2003, Rolex Rings is among the top five forging companies in India. The company manufactures hot rolled forged & machine bearing rings and automotive components. The company supplies its products in India as well as 17 different countries, which include France, Italy, Germany, Thailand, Czech Republic and USA. Nearly 55 percent of revenue comes from outside India. It has 3 manufacturing plants in Rajkot with 22 forging lines.

IPO Details –
IPO Date – 28 July to 30 July
Price band – 880 to 900rs
Lot size – 16 Shares
Proposed Listing Date – 9th august
Issue Size – 731Cr (Fresh issue – 56cr and OFS – 675cr)
Post Issue promoter Holding – 57.64%

Negative point of the company –
The revenues of the company has declined on 4 year basis.
High dependence on performance of automotive sector.
In 2013 company defaulted in payment of certain loans, and approached CDR cell for debt restructuring.

Positive point of the company –
Company has been able to significantly improve its financial profile with the debt-equity ratio improving from 1.79 times as at March 2019 to 0.70 times as of March 2021.
It has credit rating of BB with stable outlook by CARE.
Good net cash flow from operating activities.
The company earned a profit of Rs 86.95 crore in FY21 on revenues of Rs 616.33 crore and profit of Rs 52.94 crore on revenues of Rs 665.99 crore in FY20.
EPS of the company is approx 25rs. And it is available at a PE of 42 times, which is good when we compare it with industry PE of 77.

Keeping above things in mind, one may subscribe in this IPO for listing gains.

Disclaimer – Views shared is only for educational purpose. I am not a SEBI registered advisor. Please consult your financial advisor before making any investment.

If you liked this post, then consider subscribing to our YouTube channel for more such updates – https://www.youtube.com/c/equityways

27/07/2021

About Rolex Rings Limited - Incorporated in 2003, Rolex Rings is among the top five forging companies in India. The company manufactures hot rolled forged & machine bearing rings and automotive components. The company supplies its products in India as well as 17 different countries, which include France, Italy, Germany, Thailand, Czech Republic and USA. Nearly 55 percent of revenue comes from outside India....

About Rolex Rings Limited – Incorporated in 2003, Rolex Rings is among the top five forging companies in India. The company manufactures hot rolled forged & machine bearing rings and auto…

27/07/2021

GLENMARK LIFE SCIENCES LTD – Incorporated as Zorg Laboratories Private Limited in 2011, it was acquired by Glenmark Pharmaceuticals Limited in 2018. It is one of the leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) is aslo providing contract development and manufacturing operations (CDMO) services to many multinational and specialty pharmaceutical companies. 90% of the revenue comes from API business....

GLENMARK LIFE SCIENCES LTD – Incorporated as Zorg Laboratories Private Limited in 2011, it was acquired by Glenmark Pharmaceuticals Limited in 2018. It is one of the leading developer and manufactu…

27/07/2021

GLENMARK LIFE SCIENCES LTD IPO –

Incorporated as Zorg Laboratories Private Limited in 2011, it was acquired by Glenmark Pharmaceuticals Limited in 2018. It is one of the leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) is aslo providing contract development and manufacturing operations (CDMO) services to many multinational and specialty pharmaceutical companies. 90% of the revenue comes from API business. Geographically, 56% revenue comes from India and remaining 44% from foreign countries. Company has 4 manufacturing units (2 in Gujarat and 2 in Maharashtra) and 3 R&D facilities. Company exports its products to Europe, Latin America, North America, Japan, and the rest of the world.

Issue Details -
Issue Date - 27 July to 29 July
Price Band – 695 to 720rs
Lot size - 20
Issue Size - 1514cr (fresh issue – 1060cr and OFS – 454cr)
Post-Issue Market Cap - 8822 cr
Retail quota – 35%
Proposed Listing Date - 6 August
Post issue promoter holding – 83%

Negative points –
35% of its raw material comes from china.
Revenue concentration - 90% of the revenue comes from API business.
Post issue debt to equity ratio - 0.5 (which is manageable)

Positive points of the company –
IPO is priced at 25 times PE. Whereas its main competitors Divis Lab, Laurus Labs and Shilpa Medicare are trading at a P/E of 64X, 36X and 36.5X respectively.
The company has registered a 2-Yr CAGR of 45.8% and 34.1% in its sales and PAT respectively.
Strong parentage of Glenmark Pharmaceuticals.
Keeping above things in mind, one may subscribe in this IPO for listing gains.

Disclaimer – Views shared is only for educational purpose, so that you all can take a better informed decision. I am not a SEBI registered advisor. Please consult your financial advisor before making any investment.

27/07/2021

GLENMARK LIFE SCIENCES LTD IPO –

Incorporated as Zorg Laboratories Private Limited in 2011, it was acquired by Glenmark Pharmaceuticals Limited in 2018. It is one of the leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) is aslo providing contract development and manufacturing operations (CDMO) services to many multinational and specialty pharmaceutical companies. 90% of the revenue comes from API business. Geographically, 56% revenue comes from India and remaining 44% from foreign countries. Company has 4 manufacturing units (2 in Gujarat and 2 in Maharashtra) and 3 R&D facilities. Company exports its products to Europe, Latin America, North America, Japan, and the rest of the world.

Issue Details -
Issue Date - 27 July to 29 July
Price Band – 695 to 720rs
Lot size - 20
Issue Size - 1514cr (fresh issue – 1060cr and OFS – 454cr)
Post-Issue Market Cap - 8822 cr
Retail quota – 35%
Proposed Listing Date - 6 August
Post issue promoter holding – 83%

Negative points –
35% of its raw material comes from china.
Revenue concentration - 90% of the revenue comes from API business.
Post issue debt to equity ratio - 0.5 (which is manageable)

Positive points of the company –
IPO is priced at 25 times PE. Whereas its main competitors Divis Lab, Laurus Labs and Shilpa Medicare are trading at a P/E of 64X, 36X and 36.5X respectively.
The company has registered a 2-Yr CAGR of 45.8% and 34.1% in its sales and PAT respectively.
Strong parentage of Glenmark Pharmaceuticals.

Keeping above things in mind, one may subscribe in this IPO for listing gains.

Disclaimer – Views shared is only for educational purpose, so that you all can take a better informed decision. I am not a SEBI registered advisor. Please consult your financial advisor before making any investment.

07/07/2021

*Clean Science and Technology Ltd IPO*

Incorporated in 2003, it is one of the leading specialty chemical manufacturers globally. The company supplies its products in India as well as overseas markets i.e. China, Europe, USA and other countries. In fiscal 2020, it generated 69% of revenues through export outside India.
IPO Opening Date - Jul 7, 2021
IPO Closing Date - Jul 9, 2021
Issue Type - Book Built Issue IPO
Face Value - ₹1 per equity share
IPO Price - ₹880 to ₹900 per equity share
Market Lot - 16 Shares
Issue Size - ₹1546.62 Cr (Out of this all shares are by OFS, no new issue)
Proposed Listing Date Jul 19, 2021

Positive points of the company –
D/E ratio of 0.1x.
Healthy(3-year average) RoE and RoCE at 38% and 26%.
IPO is priced at 48 times PE against the average industry PE of 55 times.
Its main competitors Vinati Organics and Fine Organics are trading at 77.4PE and 75.1PE.
Keeping above things in mind, one may subscribe in this IPO for listing gains.

Disclaimer – Views shared is only for educational purpose, so that you all can take a better informed decision. I am not a SEBI registered advisor. Please consult your financial advisor before making any investment.

https://www.youtube.com/c/equityways